Zacks Investment Research upgraded shares of Rexahn Pharmaceuticals (NASDAQ:REXN) from a hold rating to a strong-buy rating in a research note issued to investors on Saturday morning, Zacks.com reports. They currently have $3.25 price objective on the stock.
According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “
A number of other brokerages have also recently issued reports on REXN. Ifs Securities cut Rexahn Pharmaceuticals from a strong-buy rating to a market perform rating in a report on Wednesday, August 7th. ValuEngine raised Rexahn Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, HC Wainwright lowered Rexahn Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Rexahn Pharmaceuticals has a consensus rating of Buy and a consensus price target of $40.75.
Rexahn Pharmaceuticals (NASDAQ:REXN) last issued its earnings results on Wednesday, August 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $0.34. Research analysts expect that Rexahn Pharmaceuticals will post -2.85 EPS for the current year.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.